Pfizer facing NICE showdown over leukaemia drug

08:44 EDT 3 Jul 2017 | pharmaphorum

Pfizer’s Besponsa leukaemia drug has been approved in Europe, but the company is heading for a showdown with England’s NICE, which has said in a draft decision that the medicine it is too expensive for regular NHS funding. Besponsa (inotuzumab...

Original Article: Pfizer facing NICE showdown over leukaemia drug


More From BioPortfolio on "Pfizer facing NICE showdown over leukaemia drug"

Quick Search


Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...